How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated

Prostate-specific membrane antigen (PSMA), also known as GCPII, has emerged as a significant target in the diagnosis and treatment of prostate cancer. This perspective highlights the journey that led to the development of PSMA-targeted urea-based ligands, culminating in the clinical success of radiopharmaceuticals such as Pylarify and Pluvicto. Originating from research at Georgetown University, early PSMA inhibitors evolved through rational drug design starting from the neurotransmitter NAAG and a phosphonic acid derivative to simplified Glu-urea scaffolds with exceptional inhibitory activity. These ligands enabled the creation of both diagnostic and therapeutic radioligands, as well as emerging small molecule drug conjugates (SMDCs). Ongoing innovation includes bifunctional antigen targeting, alternative PSMA-binding motifs, and efforts to develop brain-penetrant GCPII inhibitors. This mini-perspective reveals how a collaborative chemistry/biology project not only redefined prostate cancer imaging and therapy but also opened new avenues for targeted cancer theranostics.